Octadecanoic Acid Amide

Octadecanoic Acid Amide

SCHEMBL708299

CCCCCCCCCCCCCCCCCC(N)=O.CCO

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Octadecanoic Acid Amide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 2/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
FAAH O00519 1/20 0.68
TP53 P04637 1/20 0.68
CYP1A2 P05177 1/20 0.68
CYP3A4 P08684 1/20 0.68
CYP2C19 P33261 1/20 0.68
KDM4E B2RXH2 2/20 0.61
CES2 O00748 3/20 0.59
CES1 P23141 3/20 0.59
GPR84 Q9NQS5 7/20 0.56
PPARG P37231 6/20 0.56
PPARD Q03181 6/20 0.56
PPARA Q07869 6/20 0.56
HDAC11 Q96DB2 5/20 0.56
TSHR P16473 4/20 0.56
ALDH1A1 P00352 2/20 0.56
TLR2 O60603 2/20 0.56
TDP1 Q9NUW8 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL28267991 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53
Alcohol SCHEMBL28861099 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53
Alcohol SCHEMBL28268119 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53
Alcohol SCHEMBL28266436 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53
Tetradecanamide SCHEMBL28868494 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53
Alcohol SCHEMBL29103349 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53
Alcohol SCHEMBL28266428 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53
Alcohol SCHEMBL28266435 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53
Palmitamide SCHEMBL28266429 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53
Alcohol SCHEMBL28267994 1.00 SOAT1 (0.68) SOAT1MEN1KMT2AFAAHTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973529-A1 DISINTEGRATING LOADABLE TABLETS LifeCycle Pharma A/S (DK) 2008-10-01 EP claimed
EP-1511798-B1 METHOD FOR MAKING POLYOLEFIN NANOCOMPOSITES BASELL POLIOLEFINE SRL (IT) 2008-07-30 EP claimed
WO-2007076874-A1 DISINTEGRATING LOADABLE TABLETS LIFECYCLE PHARMA A/S (DK) 2007-07-12 WO claimed
EP-1765297-A2 POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS LifeCycle Pharma A/S (DK) 2007-03-28 EP claimed
WO-2006000229-A2 POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS LIFECYCLE PHARMA A/S (DK) 2006-01-05 WO claimed
EP-1511798-A2 METHOD FOR MAKING POLYOLEFIN NANOCOMPOSITES Basell Poliolefine Italia S.p.A. (IT) 2005-03-09 EP claimed
US-6864308-B2 Method for making polyolefin nanocomposites BASELL POLIOLEFINE ITALIA S.P.A. (IT) 2005-03-08 US claimed
WO-2003106549-A2 METHOD FOR MAKING POLYOLEFIN NANOCOMPOSITES BASELL POLIOLEFINE ITALIA S.P.A. (IT) 2003-12-24 WO claimed
US-20030232912-A1 Method for making polyolefin nanocomposites BASELL POLIOLEFINE ITALIA S.P.A (IT) 2003-12-18 US claimed
CN-118235092-A Polycyclic aromatic hydrocarbon-based photocurable resin composition 日产化学株式会社 2024-06-21 CN disclosed
WO-2023085414-A1 POLYCYCLIC AROMATIC HYDROCARBON-BASED PHOTO-CURABLE RESIN COMPOSITION 日産化学株式会社 2023-05-19 WO disclosed
CN-115135637-A Polyurethane compounds 大金工业株式会社 2022-09-30 CN disclosed
CN-113527612-A Polyurethane compounds 大金工业株式会社 2021-10-22 CN disclosed
US-11129815-B2 Solid dispersions comprising tacrolimus VELOXIS PHARMACEUTICALS INC. (US) 2021-09-28 US disclosed
WO-2002085360-A1 OPTIMIZED PROCEDURES FOR THE MANUFACTURE OF PAROXETINE SALTS PENTECH PHARMACEUTICALS, INC. (US) 2002-10-31 WO disclosed
US-20020032220-A1 Formulations comprising dissolved paroxetine SMITHKLINE BEECHAM PLC 2002-03-14 US disclosed
EP-1077685-A2 NOVEL FORMULATION CONTAINING PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-02-28 EP disclosed
EP-1033986-A1 FORMULATIONS COMPRISING DISSOLVED PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-09-13 EP disclosed
WO-1999058116-A2 NOVEL FORMULATION CONTAINING PAROXETINE SMITHKLINE BEECHAM PLC (GB) 1999-11-18 WO disclosed
WO-1999026625-A1 FORMULATIONS COMPRISING DISSOLVED PAROXETINE SMITHKLINE BEECHAM PLC (GB) 1999-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11129815-B2 Solid dispersions comprising tacrolimus TSLP, CD69, CD40LG SOAT1 2363/4885MEN1 2130/4885KMT2A 3022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.